|Bid||0.0280 x 59129200|
|Ask||0.0290 x 100647600|
|Day's range||0.0280 - 0.0290|
|52-week range||0.0140 - 0.4100|
|Beta (5Y monthly)||0.97|
|PE ratio (TTM)||N/A|
|Earnings date||29 Jul 2021 - 02 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31 March 2021 (Q3 FY21).
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced an oral presentation of expanded animal data to support the commercialisation of its lead compound ATH434 in clinical development for the treatment of Parkinsonian disorders, at the American Academy of Neurology (AAN) virtual annual meeting.
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), will present at the upcoming 7th International Congress of Multiple System Atrophy (MSA2021), to be held in a virtual format from February 26-27, 2021.